CVBT Signs Clinical Development Agreement With Cardio Neo-Genesis
Posted on: Friday, 14 November 2008, 12:00 CST
CardioVascular BioTherapeutics, a biopharmaceutical company, has entered into its first clinical development agreement for its coronary heart disease drug candidate with Cardio Neo-Genesis.
The agreement states that Cardio Neo-Genesis (CNG) can fund up to $15 million of the clinical development for the company's coronary heart disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CardioVascular BioTherapeutics's (CVBT's) cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.
Mickael Flaa, CFO of CVBT', said: "CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates. Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program.
"The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."
Source: Datamonitor
Related Articles
- Sagent and ICF Sign Development and Supply Collaboration Agreement
- Alzheimer's Drug Discovery Foundation Funds PharmatrophiX to Develop Drugs to Prevent Neurodegenerative Disease
- ICx Technologies and Siemens Medical Solutions Diagnostics Enter In Vitro Diagnostics Development and License Option Agreement
- Somanetics Signs Contract Development and Exclusive Licensing Agreement for Several Novel Technologies
- MedImmune and Infinity Pharmaceuticals Announce Cancer Drug Development and Worldwide Commercialization Agreement
- Start-Up Gets $36 Million: TetraLogic, of Malvern, is Developing Drugs That Help the Body Kill a Variety of Cancer Cells
- CytRx Enters Into Licensing Agreement With the University of Massachusetts Medical School to Develop Drugs for Newly Discovered Obesity and Type 2 Diabetes Targets
- Commentary: Techlink- Three MD-Based Firms Develop Drugs, Knowledge to Treat Problem of Obesity
- Companies to Develop Drug to Kill E.coli
- Maxim Pharmaceuticals Receives $1 Million Development Milestone Payment Under Agreement With Myriad Genetics
 |
 |
User Comments (0)
RSS Feeds